News 13.03.2024 Schlieren (Zurich), Switzerland, March 13, 2024 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next-generation bone graft technologies, today announced financial results for full year 2023 along with continued significant growth. Direct sales of MagnetOs rose 163% to CHF 31.7 million in 2023 from CHF 12.1 million in 2022. Total...
News 06.03.2024 Lisbon, Portugal - 06.03.2024 Neurimmune announced today that a Donald L. Price Memorial Lecture will be held at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD 2024, in Lisbon, Portugal and virtually from March 5 to March 9, 2024. Professor Michel Goedert, Program Leader at the...
News 28.02.2024 (BOSTON: February 27, 2024) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections. LimmaTech is a Swiss clinical stage biotech company that has built a robust pipeline of innovative vaccines to...
News 22.02.2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants...
News 14.02.2024 Switzerland, 14 February 2024 – CUTISS AG, a Swiss clinical-stage life science company focused on skin regenerative medicine and tissue engineering, has announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin™, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1...